Skip to main content
. Author manuscript; available in PMC: 2016 Jul 15.
Published in final edited form as: Cancer Res. 2015 May 15;75(14):2800–2810. doi: 10.1158/0008-5472.CAN-14-3041

Figure 6. FAP-CAR T cells impact stromagenesis and angiogenesis in murine PDA.

Figure 6

Established 4662 tumor-bearing mice (n=6 per group) and autochthonous PDA-bearing KPC mice (n=3 per group) were treated with 2 doses of FAP-CAR mouse T cells. IHC was performed using tumor tissues harvested from mice 3 days after the second dose of T cell transfer. Tumor sections were stained with antibody against (A) FAP, (B) SMA, (C) CD31, and (D) NG2. * and # denote statistical significance between MigR1 and FAP-CAR T cell-treated samples, p value < 0.01 and p value < 0.05, respectively. Scale: 100 μm.

HHS Vulnerability Disclosure